March 2024 - Page 5 of 6 - NetworkNewsWire

FridayMar 08, 2024 10:30 am

19th BioPharma Drug Discovery Nexus Conference To Cover Breakthroughs That Shape The Future Of Medicine

Scientists, C-level executives, managers, and directors from the drug discovery pharma and biotech industry verticals across Europe and North America are invited to attend the 19th BioPharma Drug Discovery Nexus Conference at the Basel, Mariott Hotel, Switzerland. A highly respected conference, this is an invite-only event where top industry leaders and executives will explore the advancements and trends in the field of drug discovery. These experts share insights and strategies that highlight the path for the future of medicine. From discussions to collaborations, this conference offers a phenomenal forum for discovering fresh perspectives and showcasing the latest technologies among a…

FridayMar 08, 2024 9:45 am

PaxMedica Inc. (NASDAQ: PXMD) Pursues Autism Treatment as Diagnostic App Shows Promise to Effective ASD Diagnosis

One in 36 children are diagnosed with autism spectrum disorder (“ASD”) – with ASD four times more common among boys than girls The SenseToKnow app accurately predicted eventual autism diagnoses in a group of 475 children – according to the study, performance was similar across sex, race, and ethnicity PaxMedica is leveraging historical data on the drug suramin to fund trials aimed at treating Autism Spectrum Disorder and Fragile X-Associated Tremor/Ataxia Syndrome According to the CDC, about 1 in 36 children are diagnosed with autism spectrum disorder (“ASD”) – with ASD four times more common among boys than girls (https://nnw.fm/23BJQ).…

FridayMar 08, 2024 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Banking on DehydraTECH(TM) Technology for Major 2024 Growth

Lexaria, a global innovator in drug delivery platforms, has, since 2016, proven its patented DehydraTECH(TM) technology, asserting its superiority in improving drug bioavailability This has earned it 39 granted patents, with many pending globally DehydraTECH has a number of potential pharmaceutical applications with successful early stage results in hypertension, diabetes and weight loss and many others With its focus on GLP-1 clinical studies for 2024, Lexaria looks to carve out greater market share to make 2024 its biggest year Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, has been pushing the envelope and redefining drug delivery technology.…

ThursdayMar 07, 2024 10:30 am

19th BioPharma Clinical Trials Nexus Conference to Host Industry Leaders Across Europe And Asia

Top executives, middle-level, and senior managers, working in clinical trial operations, outsourcing, digital health, patient engagement, and allied industries in the biopharma spectrum across Europe and North America, are invited to attend the 19th BioPharma Clinical Trials Nexus Conference at the Basel, Mariott Hotel, Switzerland. A prestigious conference, this is an invite-only event featuring top executives and eminent industry leaders. The attendees discuss practical and progressive strategies that pave the path for future trends and outcomes. The platform offers a range of fresh ideas, showcasing the latest technologies and market trends, at a parade of company presentations. Powerful speakers will…

ThursdayMar 07, 2024 9:45 am

Bravo Multinational Inc. (BRVO) Is ‘One to Watch’

Bravo, in February 2024, entered an Asset Purchase Agreement to acquire certain assets of Streaming TVEE Inc. in a deal worth $9.76 million Bravo and Pythia Experiences LLC entered an LOI to form a new company in January 2024, with Pythia owning 51%, Bravo owning 49%, Pythia contributing Vidgo Inc. and Bravo contributing a streaming platform In September 2023, the company announced it would develop an advertising-based video streaming service and app In June 2023, Bravo announced a strategic rebrand, positioning it for growth with a newly defined mission as an entertainment, hospitality and technology company The company in May…

ThursdayMar 07, 2024 9:00 am

Sekur Private Data Ltd. (CSE: SKUR) (OTCQB: SWISF) (FRA: GDT0) Promotes Email Security Solution Amid Global Conflicts and Increasing Cyber Threats

Political controversies surrounding threats to the United States’ election integrity and the international aggressions of Russia’s government underscore concerns about the ever-present need to maintain the security of personal and business communications Swiss hosted Sekur Private Data Ltd. provides a private and secure communications platform that the company is presently marketing to SMBs in the U.S. with plans to expand to other nations during the coming year SWISF provides its encrypted data protection services under Swiss Internet protocol security laws, acknowledging that Switzerland has the strictest data privacy laws in the world Sekur boasts a 100 percent-owned infrastructure and proprietary…

WednesdayMar 06, 2024 9:00 am

D-Wave Quantum Inc. (NYSE: QBTS) and NEC Australia Introduce Quantum Services to Australian Market

D-Wave and NEC Australia announced two new quantum offerings for Australia's commercial sector, federal and state governments, and academia The companies’ new quantum services aim to optimize business operations and can navigate increasingly large datasets to find solutions to real-world problems New offerings include a quantum consultancy service and access to D-Wave’s Leap(TM) real-time quantum cloud service D-Wave Quantum (NYSE: QBTS), a leader in quantum computing systems, software, and services, and NEC Australia recently announced the introduction of two new quantum services to the Australian market, enhancing the quantum computing offerings available to Australia's commercial sector, federal and state governments,…

TuesdayMar 05, 2024 9:45 am

Sigyn Therapeutics Inc. (SIGY) Therapeutic Candidates to Overcome Limitations in Healthcare

Sigyn Therapeutics is developing four medical device candidates – Sigyn Therapy(TM), ChemoPrep(TM), ChemoPure(TM), and ImmunePrep(TM) – designed to overcome current therapeutic limitations in healthcare Sigyn Therapy(TM), the company’s lead product candidate, is a single-use disposable device to treat life-threatening inflammatory conditions that are beyond the reach of drugs ChemoPrep(TM) is designed to optimize the tumor-site delivery of chemotherapy, while ChemoPure(TM) intends to reduce the toxicity of chemotherapy by sweeping off-target chemotherapy out of the bloodstream ImmunePrep(TM) is designed to reduce the presence of circulating drug decoys that interfere with the delivery of immunotherapeutic antibodies to treat cancer Medical technology company…

TuesdayMar 05, 2024 9:00 am

SenesTech Inc. (NASDAQ: SNES) Posts Fiscal Year 2023 Results; Reports Revenue Growth, and Gross Margin and Operating Expense Improvement

This success has been attributed largely to the company’s development and recent release of its Evolve soft bait product, a key addition to its growing product line Year to date 2024, SenesTech reported 80% year-to-date revenue growth compared to the same period in 2023 Going forward, the company looks to introduce a soft bait contraceptive product for mice, having proven that its products work effectively on rats SenesTech (NASDAQ: SNES), a rodent fertility control expert and the inventor of the only EPA-registered contraceptive for male and female rats, just released its financial results for the 2023 financial year. Of note…

MondayMar 04, 2024 10:30 am

Astiva Health Inc. CEO Featured Podcast Guest, Talks Commitment to Help Patients Enjoy ‘Active, Healthy and Meaningful’ Lives

In addition to providing full medical-care prescription drugs, Astiva focuses on providing rich supplemental benefits to enrollees CEO explains that “effective healthcare hinges largely on patient involvement” Astiva’s recent expansion is a crucial step in extending invaluable benefits and commitment to quality healthcare to a growing, diverse population Astiva Health CEO Dr. Tri Nguyen was the featured guest in a recent Bell2Bell Podcast release (https://nnw.fm/5Rxor). During the podcast, Nguyen talked provided an in-depth look at how Astiva Health is reshaping healthcare delivery, including an overview of the company’s commitment to patient involvement in healthcare and highlights the company’s innovative strategies in offering…

Financial news and publishing for public and private companies

Contact us: 512.354.7000

Month: March 2024